Respiratory Therapy: Pulmonary Function Testing

Pulmonary function testing is the bedrock of objective respiratory assessment, transforming subjective symptoms into measurable data that drives diagnosis and management. For you as a future clinician, mastering these tests is essential to accurately differentiate between common conditions like asthma and COPD, enabling targeted treatment that can significantly improve a patient's quality of life and prognosis.

The Essentials of Spirometry and Test Quality

Spirometry is the most common pulmonary function test, measuring how much and how quickly air can be exhaled from the lungs. Two key metrics are Forced Expiratory Volume in one second (FEV1), the volume of air forcibly blown out in the first second, and Forced Vital Capacity (FVC), the total volume of air exhaled with maximal effort. The ratio of these values, expressed as $FEV1/FVC$, is a critical diagnostic index. In healthy adults, this ratio is typically above 0.70 or 70%, indicating that a large portion of the vital capacity can be exhaled rapidly.

Accurate interpretation hinges on test quality. Reliable spirometry requires that the patient perform a forceful, complete exhalation lasting at least six seconds, with no cough or early termination. You must coach patients through proper technique: they should take a deepest possible breath, seal their lips tightly around the mouthpiece, and blast the air out as fast and completely as they can. Three acceptable maneuvers that are reproducible within 150 milliliters are needed for a valid test. Consider a patient with dyspnea; poor effort or a leak around the mouthpiece could falsely suggest a restrictive pattern, leading to misdiagnosis.

Lung Volume Measurements and Diffusion Capacity

While spirometry measures dynamic airflow, lung volume measurements assess the static volumes of air within the lungs, crucial for identifying restrictive diseases. These volumes include Total Lung Capacity (TLC), Residual Volume (RV), and Functional Residual Capacity (FRC). TLC is reduced in restrictive disorders like pulmonary fibrosis, where lung tissue is stiff and non-compliant. These volumes are typically measured using body plethysmography or gas dilution techniques, providing a complete picture of lung size that spirometry alone cannot.

Diffusion capacity testing, often called DLCO (Diffusing Capacity of the Lung for Carbon Monoxide), evaluates how effectively gases cross the alveolar-capillary membrane. A reduced DLCO indicates a problem with gas exchange, seen in conditions like emphysema (where alveolar surface area is destroyed) or interstitial lung disease (where the membrane is thickened). For instance, a patient with scleroderma may have a normal FEV1 and FVC but a significantly low DLCO, pointing to underlying pulmonary vascular or interstitial involvement that requires further investigation.

Identifying Disease Patterns with Bronchodilator Testing

Interpreting pulmonary function tests revolves around distinguishing between obstructive and restrictive patterns. An obstructive pattern, hallmark of asthma, COPD, and bronchiectasis, is characterized by reduced airflow. On spirometry, this manifests as a decreased $FEV1/FVC$ ratio (often <0.70) and a disproportionately low FEV1. Lung volumes typically show an increased TLC and RV due to air trapping.

A restrictive pattern, seen in pulmonary fibrosis, chest wall deformities, or neuromuscular weakness, shows preserved airflow but reduced lung volumes. Here, the $FEV1/FVC$ ratio is normal or even increased, but both FEV1 and FVC are reduced proportionally, and TLC is low. Bronchodilator responsiveness testing is key in obstructive diseases. After obtaining baseline spirometry, the patient inhales a short-acting bronchodilator like albuterol. The test is repeated 15-20 minutes later. A significant response—defined as an increase in FEV1 by both ≥12% and ≥200 mL from baseline—confirms reversible airflow limitation, strongly supporting a diagnosis of asthma rather than fixed obstruction like emphysema.

From Data to Decision: Guiding Asthma and COPD Management

Pulmonary function results directly inform treatment strategies. For asthma management, spirometry establishes a baseline severity (e.g., mild, moderate, severe persistent based on FEV1 percentage of predicted) and confirms diagnosis via bronchodilator responsiveness. Serial spirometry then monitors control; a declining FEV1 may signal poor adherence or the need to step up therapy. In a clinical vignette, a 25-year-old with episodic wheezing shows a pre-bronchodilator FEV1 of 65% predicted that improves to 85% post-bronchodilator. This confirms asthma, guiding initiation of inhaled corticosteroids.

For COPD management, spirometry is diagnostic and prognostic. A post-bronchodilator $FEV1/FVC$ <0.70 confirms persistent airflow obstruction. The FEV1 percentage of predicted then stages disease: GOLD 1 (mild) to GOLD 4 (very severe). This staging guides pharmacotherapy, such as long-acting bronchodilators for GOLD 2 and above, and flags patients for pulmonary rehabilitation. Additionally, a markedly reduced DLCO in a COPD patient suggests emphysema-predominant disease, which may influence discussions about surgical options like lung volume reduction. These objective measures help you move beyond symptoms alone to personalize and optimize long-term care plans.

Common Pitfalls

1. Overlooking Test Quality: Accepting suboptimal spirometry curves is a frequent error. A test with an abrupt stop or cough can artifactually reduce the FVC, falsely lowering the $FEV1/FVC$ ratio and mimicking an obstructive pattern. Correction: Always visually inspect the flow-volume and volume-time curves before interpreting numbers. Insist on reproducible, technically acceptable maneuvers.

1. Misinterpreting the FEV1/FVC Ratio in the Elderly: Rigidly applying the fixed ratio of 0.70 can lead to overdiagnosis of obstruction in healthy older adults, as the ratio normally declines with age. Correction: Use age-adjusted lower limits of normal (LLN) from reference equations when available. For a 75-year-old, a ratio of 0.68 might be within normal limits.

1. Confusing Restrictive and Obstructive Patterns: Relying solely on spirometry can be misleading. A low FVC can occur in both severe obstruction (due to air trapping preventing full exhalation) and true restriction. Correction: Always correlate with lung volume measurements. A low FVC with a normal or high TLC indicates air trapping from obstruction, while a low FVC with a low TLC confirms restriction.

1. Neglecting Patient Preparation: Failing to instruct patients to withhold certain medications before testing can obscure results. Short-acting bronchodilators should be withheld for 4-6 hours, and long-acting agents for 12-48 hours, prior to baseline testing. Correction: Provide clear, written preparation instructions, including avoiding heavy meals, smoking, and strenuous exercise before the test, to ensure accurate baseline measurements.

Summary

• Spirometry is the primary tool, with the $FEV1/FVC$ ratio central to identifying obstructive (low ratio) versus restrictive (normal/high ratio with low volumes) lung disease patterns.
• Lung volume measurements (like TLC) and diffusion capacity (DLCO) are essential for confirming restriction and assessing gas exchange, providing a complete physiological picture.
• Bronchodilator responsiveness testing is critical for diagnosing asthma and assessing reversible components of airway obstruction.
• Test quality and proper patient preparation are non-negotiable prerequisites for accurate interpretation; always review the graphical curves.
• PFT results directly guide clinical decisions: They diagnose, stage severity, monitor response to therapy, and help tailor management plans for asthma, COPD, and other respiratory conditions.